Argus CGM for Diabetes

This trial tests the ease of use of the Argus Continuous Glucose Monitoring System, a wrist-worn device that tracks blood sugar levels without piercing the skin. It is designed for individuals with type 1 diabetes, type 2 diabetes, or prediabetes. Participants will wear the Argus device and another CGM device for 15 days while continuing their daily activities. The trial primarily collects data to enhance the device and its software. Ideal candidates can maintain daily smartphone use and have a diagnosis of diabetes or prediabetes. As an unphased trial, this study allows participants to contribute to the development of innovative diabetes management technology.

The trial does not specify that you need to stop taking your current medications. You can continue your usual diabetes management throughout the study.

Research has shown that the KOS Argus Continuous Glucose Monitoring System is noninvasive, meaning it doesn't pierce the skin or insert anything into the body. This wrist-worn device uses light sensors and artificial intelligence to estimate blood sugar levels.

Although detailed studies on this device's safety in humans are lacking, its noninvasive nature suggests it could be well-tolerated. Noninvasive devices typically pose fewer risks than those requiring skin puncture. Participants in similar studies have used the device during daily activities without major issues.

The KOS Argus Continuous Glucose Monitoring (CGM) System is unique because it offers a potentially more seamless and accurate way to track glucose levels in people with diabetes. Unlike standard CGM devices, the Argus system is being tested for its ability to provide real-time glucose readings alongside a reference measurement, which could lead to improved accuracy. Researchers are excited because this system might enhance the daily management of diabetes by integrating continuous monitoring with user-friendly logging of meals, medications, and activities through a mobile app. This could make it easier for patients to maintain their target glucose levels with less hassle.

Research has shown that continuous glucose monitoring (CGM) can greatly help people with diabetes manage their blood sugar levels. In this trial, all participants will wear the investigational KOS Argus CGM System, which is unique because it doesn't use needles, making it non-invasive. Studies found this device to be 91.3% accurate in checking glucose levels using light sensors and smart technology. It also excels at detecting low blood sugar, which is crucial for avoiding emergencies. Although the Argus system is still under evaluation in this trial, these early findings offer encouragement for those managing diabetes.¹²⁵⁶⁷